Cystic Fibrosis Transmembrane Regulator Modulator Therapy Perspective: Findings in Clinical Outcomes in a Series of Pediatric Patients


  • O.C. Patran Clinical Emergency Children's Hospital of Brasov, Romania
  • L.L. Dracea Clinical Emergency Children's Hospital of Brasov, Romania; Transilvania University of Brasov, Romania



Cystic Fibrosis, CFTR, modulators, life expectancy, improvement


Cystic Fibrosis (CF) is the most frequent autosomal recessive disorder in Caucasians and has reduced life expectancy. It is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene which results in impairment of production, expression, and trafficking of the CFTR protein. CF has a multifaceted clinical representation with respiratory involvement as a main cause of morbidity and mortality. The multidisciplinary approach, care in specialized centers, early diagnosis through neonatal screening, and development of symptomatic treatments improved survival in the last decades. CFTR modulators were developed based on the discovery of the CF gene in 1989 and the improvement of genetic testing and have changed the perspective of a debilitating disease. These therapies, acting more upstream in the pathogenic cascade, overcome the underlying dysfunctions caused by CFTR mutations, having the ability to enhance or restore the resulting functional effects. CFTR modulator therapies are highly effective treatments for cystic fibrosis patients as shown in many clinical trials and real-life analyses so far. Improvement of quality of life, lung function, and pulmonary exacerbation rates are indisputable targets when evaluating the efficacy and efficiency of medical interventions in such a disease as CF, and they have been substantially changed in the era of modulators. We analyzed a small group of patients who were initiated on Kaftrio as per the indicated protocol. All significant clinical and functional aspects were improved, demonstrating the disease-changing potential of this therapy. We did not observe threatening side effects, no patients were stopped from the medication. CFTR modulators are the beginning of a new era in CF, a perspective for the improvement and effectiveness of precision medicine in CF patients.

Author Biography

L.L. Dracea, Clinical Emergency Children's Hospital of Brasov, Romania; Transilvania University of Brasov, Romania

Faculty of Medicine